Tag: Strength
-
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Condition: AsthmaInterventions: Drug: CHF 5993 100/6/12.5 µg; Drug: CHF 1535 100/6 µgSponsor: Chiesi Farmaceutici S.p.A.Not yet recruiting – verified February 2016 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
-
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Condition: AsthmaInterventions: Drug: CHF 5993 200/6/12.5 µg; Drug: CHF 1535 200/6 µg; Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µgSponsor: Chiesi Farmaceutici S.p.A.Not yet recruiting – verified February 2016 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
-
Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older
Condition: AsthmaInterventions: Drug: Treatment A: Fp MDPI; Drug: Treatment B: FS MDPI; Drug: Treatment C Flovent; Drug: Treatment D: AdvairSponsor: Teva Branded Pharmaceutical Products, R&D Inc.Not yet recruiting – verified May 2015 View full post on ClinicalTrials.gov: asthma | received in the last 14 days